About
About Alderia
GLP-1s created a new commercial map for cardiometabolic disease. Diabetes, obesity, cardiovascular disease, liver disease, kidney disease: these are no longer separate therapeutic areas with separate strategies. They share biology, patients, and market dynamics. New indications, combinations, and access pathways follow from that connection.
Capturing those opportunities requires connecting science to commercial strategy, and ensuring the people who shape prescribing, reimbursement, and market adoption are working from the same picture. That translation work is what Alderia does.
This platform tracks the signals that drive it.
Where we play
GLP-1 and obesity
Full obesity lifecycle experience: trial design, reimbursement strategy, global launch. From proof-of-concept to market adoption.
Cardiometabolic health
MASH/MASLD, liver disease, CKD, sleep apnea, endocrine, cardiovascular risk. We work at the intersection of organs, not inside a single therapeutic silo.
What we do
Medical affairs strategy and operations
Scientific platform design, KOL mapping, evidence generation, publication strategy, MSL design. From clinical data to market credibility.
Go-to-market and brand strategy
Launch strategy, brand positioning, HCP education, patient pathway design, indication sequencing. Operational delivery, not slide decks.
Stakeholder engagement, advocacy and market shaping
Decision-maker mapping, patient association coalitions, medical society engagement, payer navigation, cross-industry alliances, prescriber coalitions. We build the relationships and market conditions that make adoption possible.
How we work
Diagnostic and roadmap
1 monthFull situation audit across medical, commercial and market access. 3 strategic workshops. 5 to 10 actionable quick wins. 90-day roadmap.
Strategic lead
3 months, renewableEmbedded strategy and execution. 2 to 4 days per week. Medical affairs, launch, or access workstream leadership. Team management and supplier coordination.
Advisory retainer
Monthly, renewableA senior sparring partner. 1 hour of strategic coaching per week. Challenge and validation of key decisions. Available via Slack and email.
Alderia builds project teams from a global network of senior specialists: market access directors, HTA experts, medical affairs and communications directors, former BU heads. Average experience: 20 to 25 years in-role.
How we score signals
Every signal receives an impact score from 1 to 10. Scores are generated by AI, calibrated against three factors:
Journal weight
Publications from top-tier journals (NEJM, Lancet, Nature Medicine, JAMA) score higher than specialty journals.
Clinical significance
Sample size, study design (RCTs score higher than retrospective studies), and magnitude of reported effect.
Commercial relevance
Signals that affect competitive positioning, reimbursement strategy, regulatory pathways, or market access decisions score higher.
Scores 8 to 10: immediate strategic implications.
Scores 5 to 7: relevant but incremental.
Scores below 5: tracked for completeness.
The daily signal is selected automatically from the highest-scoring signal of the day.
Talk to Alderia about your cardiometabolic strategy.